Dr. Michael Pollak
Alexander-Goldfarb Research Chair in Medical Oncology, 平特五不中
Professor, Departments of Medicine and Oncology, 平特五不中
Director, Division of Cancer Prevention, Department of Oncology, 平特五不中
Editor-in-Chief of Cancer Prevention Research, American Association for Cancer Research (AACR)
Elected to the Royal Society of Canada (RSC), 2019
Oncology, Cancer Research, Cancer Prevention
Dr. Pollak has more than 42,500 citations of scientific contributions and more than 485 publications, with an H-index of 115.
Top 5 research publications
(Only a subset of most significant papers is listed. Please visit our website for the full list of publications from 1978-Present: /pollak-lab/publications)
Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M. Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 279: 563-6, 1998. [see also favorable editorial comment 鈥� Science 279: 475, 1998]. Impact Factor: 41.058. Times cited (as of 2021): 1,544. PMID: 9438850.
Zakikhani M, Dowling R, Fantus GI, Sonenberg N, Pollak M. Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-73, 2006. Impact Factor: 9.13. Times cited (as of 2021): 673. PMID: 17062558.
Kordes S, Pollak MN, Zwinderman AH, Math么t RA, Weterman MJ, Beeker A, Punt CJ, Richel DJ, Wilmink JW. Metformin in patients with advanced pancreatic cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 16: 839-47, 2015. Impact Factor: 36.421. Times cited (as of 2021): 121. PMID: 26067687.
Hulea L, Gravel SP, Morita M, Cargnello M, Uchenunu O, Im YK, Lehu茅d茅 C, Ma EH, Leibovitch M, McLaughlan S, Blouin MJ, Parisotto M, Papavasiliou V, Lavoie C, Larsson O, Ohh M, Ferreira T, Greenwood C, Bridon G, Avizonis D, Ferbeyre G, Siegel P, Jones RG, Muller W, Ursini-Siegel J, St-Pierre J, Pollak M, Topisirovic I. Translational and HIF-1伪-Dependent Metabolic Reprogramming Underpin Metabolic Plasticity and Responses to Kinase Inhibitors and Biguanides. Cell Metab 28(6):817-832, 2018. Impact Factor: 20.565. Times cited (as of 2021): 1. PMID: 30244971.
Pollak M. Diet boosts the effectiveness of a cancer drug. Nature 60(7719): 439-440, 2018. Impact Factor: 41.577. Times cited (as of 2021): 1. PMID: 30127476.